Navigation Links
MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
Date:9/17/2008

Study Results Published in the September 18th New England Journal of Medicine

Each year more than 52,000 Americans die from colorectal cancer. Many of these deaths could be prevented by regular screening. Yet, the vast majority of those 50 and older who should be screened for the disease are not being tested - possibly due to the cost, inconvenience, and safety concerns associated with current screening exams.

However, results of an American College of Radiology Imaging Network study published in the September 18 issue of the New England Journal of Medicine confirm that CT Colonography, often referred to as virtual colonoscopy, is an effective screening option that could be more attractive to patients and, as a result, save lives.

CT colonography employs virtual reality technology to produce a three-dimensional visualization that permits a thorough and minimally invasive evaluation of the entire colon and rectum. The ACRIN trial, sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), enrolled more than 2,600 patients at 15 sites nationwide and found that CT colonography was highly accurate for the detection of intermediate and large polyps.

For further information about the ACRIN National CT Colonography Trial, please visit: http://www.acrin.org/TabID/151/Default.aspx.

SATELLITE FEED:

Wednesday, September 17th, 2008

6:30 PM - 6:45 PM ET

AMC 3

C-Band

Transponder 3

Downlink Freq. 3760 Horizontal

NEWS: New England Journal of Medicine study confirms that CT Colonography or virtual colonoscopy, is an effective screening option that could be more attractive to patients and, as a result, save lives.

FORMAT: News Package with Extra Soundbites and B-roll

ADDITIONAL RESOURCES: Video, contact information and more available at:

SOURCE The American College of Radiology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
2. Video: New Research Discovers Independent Brain Networks Control Human Walking
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
5. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
6. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
7. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
8. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
9. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
10. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
11. Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4Protecting humans and animals from diseases in wildlife 10285 1Protecting humans and animals from diseases in wildlife 10285 2New Singapore France research alliance to develop state of the art nanotechnologies 10281 1New Singapore France research alliance to develop state of the art nanotechnologies 10281 2New Singapore France research alliance to develop state of the art nanotechnologies 10281 3MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 1MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 2MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 3MedicAlert Foundation International and CAP STS Collaborate to Standardize Emergency Medical Information 59051 4